Education
About Us
Working with TipRanks
Follow Us
ArriVent BioPharma, Inc. (AVBP)
NASDAQ:AVBP
AVBP Stock Chart & Stats
$19.62
$0.14(0.52%)
At close: 4:00 PM EST
$19.62
$0.14(0.52%)
Day’s Range― - ―
52-Week Range$15.47 - $29.71
Previous CloseN/A
Volume49.09K
Average Volume (3M)426.96K
Market Cap
$809.94M
Enterprise Value$526.49M
Total Cash (Recent Filing)$300.27M
Total Debt (Recent Filing)$56.00K
Price to Earnings (P/E)―
Beta0.97
Next Earnings
Mar 26, 2026EPS Estimate
-0.87Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.83
Shares Outstanding41,281,360
10 Day Avg. Volume415,001
30 Day Avg. Volume426,960
Financial Highlights & Ratios
PEG Ratio-0.58
Price to Book (P/B)3.25
Price to Sales (P/S)0.00
P/FCF Ratio-11.94
Enterprise Value/Market Cap0.65
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-3.36
Forecast
1Y Price Target
$41.33Price Target Upside110.65% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-3.9
Revenue Forecast (FY)$650.00K
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyFirmonertinib demonstrated a high confirmed overall response rate at the higher-dose cohort, supporting meaningful efficacy in underserved EGFR-mutant lung cancer subtypes.
Commercial PreparednessAppointment of an experienced chief commercial officer signals active preparations for potential U.S. launch and broader commercialization efforts.
Regulatory PathwayGlobal Phase 3 head-to-head ALPACCA trial versus osimertinib/afatinib includes an interim analysis on response and progression that could enable accelerated approval, with topline data expected in early 2026.
Bears Say
Competitive PressureDirect competition from Oric's enozertinib and the use of Rybrevant in U.S. treatment regimens could constrain firmonertinib's market share and pricing power in first- and second-line settings.
Investor Sentiment And VolatilityHigh short interest at roughly 27.5% of the float reflects notable bearish investor sentiment that could amplify share-price volatility and pressure the stock if clinical outcomes disappoint.
Tolerability RiskA dose reduction rate near 80% indicates substantial tolerability issues that could reduce effective dosing and limit clinical benefit in real-world use.
ArriVent BioPharma, Inc. News
AVBP FAQ
What was ArriVent BioPharma, Inc.’s price range in the past 12 months?
ArriVent BioPharma, Inc. lowest stock price was $15.47 and its highest was $29.71 in the past 12 months.
What is ArriVent BioPharma, Inc.’s market cap?
ArriVent BioPharma, Inc.’s market cap is $809.94M.
When is ArriVent BioPharma, Inc.’s upcoming earnings report date?
ArriVent BioPharma, Inc.’s upcoming earnings report date is Mar 26, 2026 which is in 74 days.
How were ArriVent BioPharma, Inc.’s earnings last quarter?
ArriVent BioPharma, Inc. released its earnings results on Nov 10, 2025. The company reported -$0.83 earnings per share for the quarter, missing the consensus estimate of -$0.789 by -$0.041.
Is ArriVent BioPharma, Inc. overvalued?
According to Wall Street analysts ArriVent BioPharma, Inc.’s price is currently Undervalued.
Does ArriVent BioPharma, Inc. pay dividends?
ArriVent BioPharma, Inc. does not currently pay dividends.
What is ArriVent BioPharma, Inc.’s EPS estimate?
ArriVent BioPharma, Inc.’s EPS estimate is -0.87.
How many shares outstanding does ArriVent BioPharma, Inc. have?
ArriVent BioPharma, Inc. has 41,281,360 shares outstanding.
What happened to ArriVent BioPharma, Inc.’s price movement after its last earnings report?
ArriVent BioPharma, Inc. reported an EPS of -$0.83 in its last earnings report, missing expectations of -$0.789. Following the earnings report the stock price went up 3.104%.
Which hedge fund is a major shareholder of ArriVent BioPharma, Inc.?
Currently, no hedge funds are holding shares in AVBP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ArriVent BioPharma, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$41.33 (110.65% Upside)
$41.33 (110.65% Upside)
Blogger Sentiment
Bullish
AVBP Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 146.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.7%
Last 30 Days ▲ 0.5%
Last 30 Days ▲ 0.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-26.95%
12-Months-Change
Fundamentals
Return on Equity
-51.98%
Trailing 12-Months
Asset Growth
11.56%
Trailing 12-Months
Company Description
ArriVent BioPharma, Inc.
ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
AVBP Stock 12 Month Forecast
Average Price Target
$41.33
▲(110.65% Upside)
Technical Analysis
uniQure
―
Iovance Biotherapeutics
―
Relay Therapeutics
―
Inventiva
―
Taysha Gene Therapies
―
Ownership Overview
Currently, No data available
---